3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]-benzamide | 702674-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]-benzamide
• 英文别名: 3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]pyrimidin-2-yl]amino]benzamide
• CAS: 702674-44-0
• 化学式: C₁₆H₁₆BrN₇O
• 分子量: 402.253
• InChiKey: QLKRALJYJFRBSF-UHFFFAOYSA-N

物化性质

• 沸点：
  759.2±70.0 °C(Predicted)
• 密度：
  1.641±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
  申请人：——

  公开号：US20040186118A1

  公开（公告）日：2004-09-23

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases

  本发明涉及一种通式（I）的嘧啶衍生物，作为激酶抑制剂，其制备以及它们作为治疗各种疾病的药物的用途。
• Formylated N-heterocyclic derivatives as FGFR4 inhibitors
  申请人：Buschmann Nicole

  公开号：US10189813B2

  公开（公告）日：2019-01-29

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了一种式（I）化合物或其药学上可接受的盐； 一种制造所述化合物的方法及其治疗用途。本发明进一步提供了一种药理活性剂组合和包含所述化合物的药物组合物。
• Stable, concentrated radionuclide complex solutions
  申请人：Advanced Accelerator Applications (Italy) Srl

  公开号：US10596276B2

  公开（公告）日：2020-03-24

  The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

  本发明涉及高浓度和高化学稳定性的放射性核素复合物溶液，这种溶液可用作诊断和/或治疗目的的药物产品。药品的稳定性是通过至少一种防止放射性降解的稳定剂来实现的。在生产过程的不同阶段使用两种稳定剂具有特别的优势。
• FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS
  申请人：NOVARTIS AG

  公开号：EP3274344B1

  公开（公告）日：2019-04-24
• METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
  申请人：Advanced Accelerator Applications S.A.

  公开号：EP3826687A1

  公开（公告）日：2021-06-02